• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Three rationale documents from VetCast available for comments

The EUCAST Veterinary committee has released three rationale documents for consultation (comments no later than 8 January, 2024)

Get to know more

Company Rationale Document template revised

Companies are requested to complete a "company rationale document" to aid the EUCAST process of setting breakpoints for new agents. A template has been available for many years. It is now revised .

Get to know more

Rationale Documents

Rationale Documents EUCAST rationale documents summarise the information on which the EUCAST clinical breakpoints are based. Bedaquiline Rationale for EUCAST clinical breakpoints Version 1.3, 4 July 2019 Download PDF Bedaquiline (TMC207) is a diarylquinoline, a new class of anti-tuberculosis (TB)…

Get to know more

VetCAST

Veterinary Committee on Antimicrobial Susceptibility Testing (VetCAST) VetCAST is a EUCAST subcommittee dealing with all aspects of antimicrobial susceptibility testing of bacterial pathogens of animal origin and animal bacteria with zoonotic potential. Subcommittee Discover More Development of…

Get to know more

Rationale Documents updated to new format

EUCAST is currently in the process of reviewing and updating the format of all rationale documents . It is a major and very resource consuming task. Three RDs (cefiderocole, ceftriaxone, tigecycline) have now been published in the the new format, one of which did not previously exist. Old versions…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs The EUCAST AMST develops breakpoints and methods for antimicrobial susceptibility testing of mycobacteria. Rationale Documents Discover More Public Consultations A chance to review proposed EUCAST changes. Discover More Submit non-truncated MIC…

Get to know more

Development of clinical breakpoints and ECOFFs

Development of clinical breakpoints and ECOFFs How to collect and handle PK data Supporting information Guideline VetCAST PK analysis Author: VetCAST Date 06/04/18 Download PDF Guideline to collect, archive, handle and analyse pharmacokinetic data for VetCAST The purpose of this Guideline document…

Get to know more

Reference Method

Reference Method The EUCAST reference method for the Mycobacterium tuberculosis complex is broth microdilution in Middlebrook 7H9. See following documents for further information. EUCAST reference protocol for MIC determination of anti-tuberculous agents against isolates of the Mycobacterium…

Get to know more

Candida auris with EUCAST breakpoints (preprint)

How to interpret MICs of amphotericin B, echinocandins and flucytosine againstCandida auris(Candidozyma auris) according to the newly established EUCAST breakpoints. Maiken Cavling Arendrup et al. CMI 2025 (preprint) Objectives. The aim was to present an overview of the newly established ECOFFs and…

Get to know more

Industry

Information for pharmaceutical companies intending to bring new antimicrobial drugs to EUCAST for breakpoints The development of clinical breakpoints for new agents requires agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions,…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here